Want to join the conversation?
$ROP 2Q15 Call: Organic revenue in Medical was up at 2%, but if you adjust it for rugged mobile discontinuance, organic revenue would have been higher. FX was a 3% headwind in quarter for Medical, but overall revenue grew at 13%, operating profit was up 18%, & operating margin was 36.6%. We had double digit growth in our Medical device businesses.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.